Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Celgene Corporation
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046
The primary objective of the study is to collect survival/vital status of CA046 subjects who were known to be alive at the last report of vital status for CA046
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia (β-thalassemia)
To determine a safe, tolerable and effective dose of sotatercept in adult subjects with RBC transfusion-dependent beta-thalassemia major (including all subtypes)and β thalassemia intermedia, as well a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
To evaluate the efficacy of two dose regimens of lenalidomide in subjects with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to measure how safe CC-220 is and how well CC-220 works in people with lupus. Estudio para medir como es de seguro el CC-220 y como de bien funciona en personas con lupus
To evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) usin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to decide what is the highest dose of CC-220 to take alone and with dexamethasone to assess the side effects, effectiveness and how the body deals with the drug in patients with multiple myeloma that recurs or is resistant to already tried medicines by patients
To determine the maximum tolerated doses (MTDs) of CC-220 as monotherapy (MonoT) and in combination with dexamethasone (DEX) (DoubleT) in subjects with RRMM
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy
The primary objective is to demonstrate superiority in overall survival of amrubicin (40 mg/square metre administered as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Study at several sites to evaluate pomalidomide taken with dexamethasone (low dose) in patients with Multiple Myeloma (MM) and impaired kidney function who did not respond to the previous treatment or whose disease has returned after the previous treatment
Evaluate efficacy of the combination of pomalidomide and low-dose dexamethasone in subjects with RRMM and impaired renal function.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6